Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.
about
Oxidative stress associated with middle aging leads to sympathetic hyperactivity and downregulation of soluble guanylyl cyclase in corpus cavernosumCardioprotective effects of PKG activation by soluble GC activator, BAY 60-2770, in ischemia-reperfusion-injured rat hearts.Induction of microRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in miceCatestatin increases the expression of anti-apoptotic and pro-angiogenetic factors in the post-ischemic hypertrophied heart of SHR.Anti-inflammatory and cardioprotective effects of tadalafil in diabetic miceDevelopment of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Soluble guanylate cyclase as a novel treatment target for osteoporosis.PDE5 inhibitors as therapeutics for heart disease, diabetes and cancerSynthetic Peptides as cGMP-Independent Activators of cGMP-Dependent Protein Kinase IαThe soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitusHydrogen sulfide and PKG in ischemia-reperfusion injury: sources, signaling, accelerators and brakes.Soluble guanylate cyclase activation during ischemic injury in mice protects against postischemic inflammation at the mitochondrial level.Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice.Adalimumab ameliorates abdominal aorta cross clamping which induced liver injury in rats.Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation.Protein S-nitrosylation in preconditioning and postconditioning.The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism.Hydrogen sulfide mediates the cardioprotective effects of gene therapy with PKG-Iα.Treatment with hydrogen sulfide alleviates streptozotocin-induced diabetic retinopathy in rats.NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.Hormesis, cell death, and regenerative medicine for neurode-generative diseases.Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil.Breathing nitric oxide plus hydrogen gas reduces ischemia-reperfusion injury and nitrotyrosine production in murine heart.Nongenomic thyroid hormone signaling occurs through a plasma membrane-localized receptor.Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice.Pre- and postconditioning the heart with hydrogen sulfide (H2S) against ischemia/reperfusion injury in vivo: a systematic review and meta-analysis.International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors.Influence of cinaciguat on gastrointestinal motility in apo-sGC mice.Etanercept protects myocutaneous flaps from ischaemia reperfusion injury: An experimental study in a rat tram flap model.Comparative Studies of the Dynamics Effects of BAY60-2770 and BAY58-2667 Binding with Human and Bacterial H-NOX Domains
P2860
Q28247831-951F1045-9E96-4CAB-8439-2AD90F6845CDQ33865769-07F094F1-C660-4491-88E6-D9903C7869E0Q33874591-0626E1D2-184E-4268-9BB5-FDEDDF39F8BBQ34010818-9379EA63-CBDC-40E9-B829-B3288CE0B322Q34428464-63ADA468-14F6-43F4-BBD5-E3FF047EA2F7Q34538482-D95BF366-0340-4C5E-AC94-FD7F871056F0Q34551704-A12D5170-077D-46CE-B08D-D88C20BAD213Q35827798-C42BF4C9-EA64-4386-B715-A191A8AEB374Q35873815-3916684C-1322-4CE2-B75F-4A05659C732EQ36234790-ED8CB053-AD72-4E70-89F1-096147AA393EQ36341617-B7898F46-C349-454D-A19A-15F910748717Q36902247-BDA93B13-21F8-44CF-8E4F-B5ADB92CA2A1Q37476512-509632A6-FEF6-4BD2-9642-1C8F5BA2EA83Q37556557-8E21E391-1751-416D-A192-7A5CD92C6ACFQ38191314-5D65B428-7262-40C4-9678-13BAB9FBA407Q38199441-AD9972BA-7267-4518-BC8C-BD1036CA9084Q38258238-B7AD22A9-60AA-4996-933A-40D228ED14A1Q41189484-D04A7461-3303-431A-B3D9-D161E721D5E7Q41851278-A614917F-9448-4C76-9C77-4F5C0CEDFC08Q41879996-AA1A0FA0-167B-47D2-8702-2500F4120891Q42154661-6A7F6252-0CE7-48C7-B06D-B9B70CBBF1D2Q44529978-C5DE4477-7E37-41D0-AB84-BB8BE4EAEBE4Q44904552-62E717F7-1D3B-45CF-BB12-6E4EFEF9C7A6Q46551375-6BF1E26F-CA7D-4B62-97D7-6E4FFD393E48Q46556756-FE6967F5-99C3-4B7F-9FA0-95E3B0C86078Q47141923-1960BAF2-7AC7-44D1-BDB5-964D0035B09AQ47914860-57830873-3878-4319-984E-BB0483CCF4A2Q49047822-1839E1B1-9238-4DBE-8571-62354E7FC0A9Q51463246-5251D54C-507D-4579-97D2-BAC5B26F38A7Q58696712-B400345F-50D0-4970-A798-427D0AA28B0B
P2860
Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cinaciguat, a novel activator ...... ury: role of hydrogen sulfide.
@ast
Cinaciguat, a novel activator ...... ury: role of hydrogen sulfide.
@en
type
label
Cinaciguat, a novel activator ...... ury: role of hydrogen sulfide.
@ast
Cinaciguat, a novel activator ...... ury: role of hydrogen sulfide.
@en
prefLabel
Cinaciguat, a novel activator ...... ury: role of hydrogen sulfide.
@ast
Cinaciguat, a novel activator ...... ury: role of hydrogen sulfide.
@en
P2093
P2860
P1476
Cinaciguat, a novel activator ...... jury: role of hydrogen sulfide
@en
P2093
Fadi N Salloum
Johannes-Peter Stasch
Nicholas N Hoke
Rakesh C Kukreja
Ramzi A Ockaili
Vinh Q Chau
P2860
P304
P356
10.1152/AJPHEART.00544.2011
P577
2012-01-20T00:00:00Z